Altria and Lexaria Conclude Phase I Research and Development Program

Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that Phase I of the research and development…

Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that Phase I of the research and development program of oral forms of nicotine delivery utilizing Lexaria’s patented DehydraTECHTM technology with Altria Ventures Inc. (“Altria”) has concluded. The Phase I research and development program was initiated to evaluate reduced […]

The post Altria and Lexaria Conclude Phase I Research and Development Program appeared first on Technical420.

Leave a Reply

Your email address will not be published. Required fields are marked *